Limestone Investment Advisors’s Boston Scientific BSX Stock Holding History

Limestone Investment Advisors’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,300	Closed	-$1.01M	–	480
2025 Q3	$1.01M	Buy	10,300 +700	+7%	+$72.5K	0.08%	171
2025 Q2	$1.03M	Buy	+9,600	New	+$971K	0.09%	182

Other funds holding BSX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Limestone Investment Advisors's BSX Position: Q4 2025 in Review

Limestone Investment Advisors sold out of Boston Scientific (BSX) in Q4 2025, closing a stake of 4,582 shares — an estimated $447K sold.

Limestone Investment Advisors first reported a position in BSX in Q2 2025 and held it in 2 quarters. The position peaked at $447K in Q3 2025. 1,785 funds tracked by Wall St. Rank hold BSX as of Q4 2025.

Limestone Investment Advisors reported no remaining Boston Scientific position as of Q4 2025 after selling out during the quarter.
Limestone Investment Advisors sold 4,582 Boston Scientific shares in Q4 2025, an estimated $447K.
Limestone Investment Advisors first reported a position in Boston Scientific in Q2 2025 and held it in 2 quarters.
Limestone Investment Advisors's Boston Scientific position peaked at $447K in Q3 2025.
1,785 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2025.

Based on Limestone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.